Alprazolam manufacturing factory busted in Valsad, drugs worth ₹22 crores seized; four held

New Delhi:  In a major blow to the synthetic drugs manufacturing, the Directorate of Revenue Intelligence (DRI) has busted a clandestine factory located in a sparsely populated area off the Gujarat State Highway (SH) 701, in Valsad, Gujarat, The factory engaged in production of Alprazolam, a psychotropic substance under the NDPS Act, 1985.

The operation codenamed “Operation White Cauldron” resulted in the seizure of Alprazolam worth ₹22 crore and the arrest of four persons, including the masterminds, who are financiers and manufacturers, as well as the intended recipient of the drug.

Acting on specific intelligence, DRI officers mounted discreet surveillance on the identified manufacturing facility. On 4th November 2025, a swift and coordinated raid was conducted, which led to uncovering a full-scale illegal manufacturing unit. The search resulted in the seizure of the following:

  • 9.55 kg of Alprazolam (finished form)
  • 104.15 kg of Alprazolam (semi-finished form)
  • 431 kg of raw materials, including key chemicals such as p-Nitrochlorobenzene, Phosphorous Pentasulfide, Ethyl Acetate, and Hydrochloric Acid
  • Full industrial-scale processing setup, including reactors, centrifuge, industrial refrigeration unit, and heating mantle.

The operation led to the arrest of two key persons, directly involved in the manufacturing and financing of Alprazolam, and an employee assisting them in production. The recipient of the drug, who had come from Telangana to collect it, was also apprehended, bringing the total arrests to four.

Preliminary investigation revealed that the manufactured Alprazolam was intended for supply to Telangana, potentially for mixing in Toddy. Notably, the DRI had busted a similar Alprazolam manufacturing unit in August 2025 in Atchuthapuram, Anakapalli District, Andhra Pradesh. The seized 119.4 kg of Alprazolam was also destined for Telangana for mixing with Toddy.

This year itself, the DRI has dismantled four clandestine drugs manufacturing facilities through intelligence-driven operations, underscoring its continuous vigilance, operational excellence, and unwavering commitment to the Government’s Nasha Mukt Bharat Abhiyaan by protecting citizens from the menace of narcotic and psychotropic substances.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre